Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-12-20FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for STEGLUJAN (ertugliflozin and sitagliptin) from Merck, indicating an update to its labeling a…
-
FDA approval · 2024-12-20FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Segluromet (ertugliflozin and metformin hydrochloride) by Merck Sharp & Dohme LLC.
-
FDA approval · 2024-12-18FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) submitted by Janssen Pharmaceutical…
-
FDA approval · 2024-12-18FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET (canagliflozin and metformin hydrochloride) filed by Janssen Pharmaceuticals.
-
FDA approval · 2024-12-11FDA Approved: METFORMIN HYDROCHLORIDE ORAL SOLUTION — Supplemental Application (TRUPHARMA, LLC)
FDA approved a supplemental application for Metformin Hydrochloride Oral Solution from TruPharma, LLC to market this generic product.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-09FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Ozempic (oral semaglutide) submitted by Novo Nordisk. The action concerns the oral formulation r…
-
EMA approval · 2024-11-28EMA Authorised: Xultophy (insulin degludec;liraglutide) — Novo Nordisk A/S
The European Medicines Agency authorised Xultophy, a fixed-dose combination of insulin degludec and liraglutide, for adults with type 2 diab…
-
FDA approval · 2024-11-25FDA Approved: INSULIN GLARGINE — Supplemental Application (Biocon Biologics Inc.)
FDA approved a supplemental application for INSULIN GLARGINE-YFGN from Biocon Biologics Inc., authorizing its biosimilar insulin glargine pr…
-
EMA approval · 2024-11-21EMA Authorised: Bydureon (exenatide) — AstraZeneca AB
The European Medicines Agency authorised Bydureon (exenatide extended-release) for type 2 diabetes mellitus, with AstraZeneca AB as the mark…
-
FDA approval · 2024-11-19FDA Approved: EXENATIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal's original application for a generic version of exenatide for adults with type 2 diabetes.
-
EMA approval · 2024-11-06EMA Authorised: Byetta (exenatide) — AstraZeneca AB
The EMA authorised Byetta (exenatide) for the treatment of Type 2 diabetes mellitus; decision date: 05 November 2024.
-
FDA approval · 2024-11-01FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for BYETTA (exenatide) submitted by AstraZeneca Pharmaceuticals LP.
-
FDA approval · 2024-11-01FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for liraglutide, updating the drug's labeling/indication.
-
FDA approval · 2024-11-01FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for Ozempic to expand its options by approving the oral semaglutide formulation for adults with type…
-
FDA approval · 2024-11-01FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for TRULICITY (dulaglutide) from Eli Lilly and Company.
-
FDA approval · 2024-11-01FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application to authorize SOLIQUA 100/33, a fixed-ratio combination of insulin glargine and lixisenatide, for the…
-
FDA approval · 2024-11-01FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for XULTOPHY 100/3.6 (insulin degludec and liraglutide) from Novo Nordisk, expanding the product's a…
-
EMA approval · 2024-10-25EMA Authorised: Suliqua (insulin glargine;lixisenatide) — Sanofi Winthrop Industrie
The EMA authorised Suliqua, a fixed-dose combination of insulin glargine and lixisenatide, for the treatment of Type 2 diabetes mellitus; th…
-
FDA approval · 2024-10-18FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approves METFORMIN HYDROCHLORIDE from Aurobindo Pharma Limited under an original ANDA for the treatment of type 2 diabetes mellitus.
-
FDA approval · 2024-09-27FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for metformin hydrochloride from Sun Pharmaceutical Industries, Inc.
-
EMA approval · 2024-09-23EMA Authorised: Repaglinide Accord (repaglinide) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Accord Healthcare S.L.U.'s Repaglinide Accord for the treatment of type 2 diabetes mellitus.
-
FDA approval · 2024-08-29FDA Approved: TOUJEO — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for Toujeo (insulin glargine) from Sanofi-Aventis U.S. LLC.
-
EMA approval · 2024-08-27EMA Authorised: Pioglitazone Accord (pioglitazone hydrochloride) — Accord Healthcare S.L.U.
The EMA authorised Pioglitazone Accord (pioglitazone hydrochloride) for the treatment of Type 2 diabetes mellitus under Accord Healthcare S.…
-
FDA approval · 2024-08-23FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2024-08-23FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET (canagliflozin and metformin hydrochloride) submitted by Janssen Pharmaceuticals, Inc.…